Latest News
Baidu Surges on AI Cloud Strength Despite Advertising Decline
Baidu's U.S.-listed shares rallied over 3% premarket as Q1 revenue topped forecasts, with AI cloud revenue surging 49% to offset a 22% drop in online marketing.
Crude Surge Puts Ethereum Under Pressure, Lee Warns of Macro Headwinds
Ether fell to ~$2,100 as oil's jump above $100 reignited inflation fears. Fundstrat's Tom Lee flags crude as Ethereum's top headwind, with record negative correlation.
Cisco's AI Surge Lifts Nokia; Earnings Test Looms
Nokia shares rose 1.2% after Cisco's $5.3B AI orders boosted networking stocks. Nokia's Q1 AI/cloud sales jumped 49%, but high valuation and competition keep the bar high.
Redwire Stock Holds Steady After 27% Rally, Focus Shifts to Defense Showcase
Redwire shares traded flat Monday after a 27% rally last week, as the market awaits updates from the SOF Week defense event in Tampa and assesses the company's $498.1 million backlog.
XRP Retreats to $1.38 Amid Broad Crypto Selloff Despite ETF Inflows
XRP slid to $1.38 on Monday, down 2.29%, as a broad crypto selloff erased gains from last week. Despite $60.5M in spot ETF inflows, the token extended losses, with traders watching Fed minutes and US crypto legislation.
Regeneron Shares Slide After Melanoma Combo Misses Key Goal
Regeneron shares tumbled 11.8% in premarket trading after its melanoma drug combo missed statistical significance on progression-free survival versus Keytruda.
Bitcoin Slides Below $77K as Rising Bond Yields and Oil Prices Squeeze Crypto Markets
Bitcoin dropped to $76,753 on Monday, pressured by higher bond yields, rising oil prices, and $661 million in forced liquidations. The Federal Reserve's meeting minutes are next.
Sunshine Biopharma Rebounds Premarket After Dilution Fears
Sunshine Biopharma shares jumped 147% in premarket trading Monday after Friday's steep fall, as traders reacted to a $6 million share-and-warrant registration and a quarterly net loss.
Compass Pathways Surges Premarket on Accelerated FDA Review for Psilocybin Drug
Compass Pathways shares surged 19.5% in premarket trading after the FDA cleared a faster review path for its COMP360 psilocybin depression treatment. The company will discuss next steps at the RBC Capital Markets conference.
Futures Dip as Oil Surge, Rising Yields Weigh; Nvidia, Retail in Focus
Dow futures slid 300 points Monday as oil stayed above $100 and Treasury yields hit 15-month highs. Nvidia's earnings and Walmart's report are in focus this week.